Anti-PRKD2 antibody produced in rabbit

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

PRKD2 (protein kinase D 2) acts as a potential effector of GABPs in hematopoietic stem cells (HSCs) and mediates the transformation of HSCs by BCR (breakpoint cluster region) - ABL (Abelson) tyrosine kinase oncogene that results in CML (chronic myelogenous leukemia). The protein is considered to be a unique element of signal transduction pathway initiated by phorbol esters and the CCKB/gastrin receptor.
In gastrointestinal tumors and gliomblastomas PRK2 (protein kinase D 2) controls the communication between tumor cells and endothelial cells. PRK2 gets activated by various stimuli such as hypoxia, reactive oxygen species and receptor tyrosine kinases. In human cancers, PRKD2 actively participate in dedifferentiation, survival, formation of new blood vessels and invasion.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

PRKD2 (protein kinase D 2) is a member of calcium/calmodulin-dependent protein kinase superfamily. Phorbol esters effectively activate PRKD2 protein by binding to its two N-terminal cysteine rich domains. The protein is expressed in cytoplasm and nucleus.

Serine/threonine-protein kinase D2 recombinant protein epitope signature tag (PrEST)

Corresponding Antigen APREST74594

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany